Pesquisas alternativas:
doses developing » does developing (Expandir a Pesquisa), cases developing (Expandir a Pesquisa), costs developing (Expandir a Pesquisa)
care developing » late developing (Expandir a Pesquisa), care development (Expandir a Pesquisa)
developing type » developing novel (Expandir a Pesquisa)
drug doses » drug dose (Expandir a Pesquisa), drug disease (Expandir a Pesquisa)
drug care » drugs care (Expandir a Pesquisa), drug card (Expandir a Pesquisa), drug case (Expandir a Pesquisa)
doses developing » does developing (Expandir a Pesquisa), cases developing (Expandir a Pesquisa), costs developing (Expandir a Pesquisa)
care developing » late developing (Expandir a Pesquisa), care development (Expandir a Pesquisa)
developing type » developing novel (Expandir a Pesquisa)
drug doses » drug dose (Expandir a Pesquisa), drug disease (Expandir a Pesquisa)
drug care » drugs care (Expandir a Pesquisa), drug card (Expandir a Pesquisa), drug case (Expandir a Pesquisa)
1
2
“... risks we considered the relevance to AD drug development of the following factors: (1) effective dosing...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
3
“... dependent on the drug’s pharmacological action and dose. Common Type B reactions seen in clinical practice...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
4
Por Coenen, Martin, Hinze, Annette Viktoria, Mengel, Martin, Fuhrmann, Christine, Lüdenbach, Bastian, Zimmermann, Julian, Dykstra, Verena, Fimmers, Rolf, Viviani, Roberto, Stingl, Julia, Holdenrieder, Stefan, Müller, Marcus, Hartmann, Gunther, Coch, Christoph
Publicado no BMC Pharmacol Toxicol (2015)
“... the dose steps within the first-in-human trial with a newly developed RIG-I ligand. Thus, ResI is a...”Publicado no BMC Pharmacol Toxicol (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
“... of lactose in drugs is often limited.
This data could positively impact the quality of care for lactose...”
Obter o texto integral
Obter o texto integral
Artigo
6
Por Field, Terry S, Rochon, Paula, Lee, Monica, Gavendo, Linda, Baril, Joann L, Gurwitz, Jerry H
Publicado em 2010
“...-term care facility. Randomization was within blocks by unit type. Alerts related to medication...”Publicado em 2010
Obter o texto integral
Obter o texto integral
Artigo
7
“... characterized as mild, moderate, or severe and as type A (dose-dependent or predictable) or type B...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
Por Currie, Olivia, Mangin, Dee, Williman, Jonathan, McKinnon-Gee, Bianca, Bridgford, Paul
Publicado em 2013
“... clear dose response effect. However, patients prescribed statins have a higher background risk...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
9
Por Vladimir T. Ivashkin, Andrey Yu. Baranovsky, Karina L. Raikhelson, Lyudmila K. Palgova, Marina V. Maevskaya, Elina A. Kondrashina, Natalya V. Marchenko, Tatyana P. Nekrasova, Igor G. Nikitin
Publicado em 2019-03-01
Assuntos:
“...drug-induced liver injuries...”Publicado em 2019-03-01
Obter o texto integral
Artigo
10
Por N. V. Vostokova, Yu. A. Trakhtenberg, E. A. Smolyarchuk, A. A. Svistunov
Publicado em 2018-02-01
Assuntos:
“...drugs...”Publicado em 2018-02-01
Obter o texto integral
Artigo
11
12
Por Jiang, Wei, Mautner, Victor-F., Friedrich, Reinhard E., Kluwe, Lan
Publicado no J Clin Neurol (2015)
“... to two cytotoxic drugs (nilotinib and imatinib) were measured by following dose-dependent changes...”Publicado no J Clin Neurol (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
13
Por Mary M. Torregrossa, Jacqueline M. Barker, Shannon L. Gourley
Publicado no Frontiers Research Topics (2018)
“... associated with the risk for developing a substance use disorder later in life. Furthermore, adolescent drug...”Publicado no Frontiers Research Topics (2018)
Obter o texto integral
Livro
14
Por Panda, Abinash, Pradhan, Supriya, Mohapatra, Gurukrushna, Mohapatra, Jigyansa
Publicado no Indian J Pharmacol (2016)
“... to the non-self-medication group (11.97%). DRP related to inappropriate drug dosing was observed in 44.83...”Publicado no Indian J Pharmacol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
15
“...Background. Drug resistance development in the human immunodeficiency virus (HIV)-infected...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
Por Roberta Simone Andreazza, Mauro Silveira De Castro, Patrícia Sippel Köche, Isabela Heineck
Publicado em 2011-12-01
Assuntos:
“...Drug-related problem...”Publicado em 2011-12-01
Obter o texto integral
Artigo
17
Por Mezaki, T, Kaji, R, Hamano, T, Nagamine, T, Shibasaki, H, Shimizu, T, Kimura, J
Publicado em 1994
“...Twenty two patients with cervical and axial dystonias were treated with Japanese type A botulinum...”Publicado em 1994
Obter o texto integral
Obter o texto integral
Artigo
18
Por Duncan, Ruth, Sat-Klopsch, Yee-Nee, Burger, Angelika M., Bibby, Michael C., Fiebig, Heinz H., Sausville, Edward A.
Publicado em 2013
“... calibrated with respect to functional vascular permeability and/or mechanisms controlling intratumoural drug...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
“.... METHODS: Design development goals were established, and validation tests (dose accuracy, torque/force...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
20
“... in patients with type 2 diabetes, focusing on patient selection, simple dosing and titration, and monitoring...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo